Amylyx Pharmaceuticals closed at $29.40 on Nov 4, up 0.68%, 25.9% below its 52-week closing high. Volume of 1.6M shares was 1.20× its 20-day average (close to normal).
Split-adjusted performance: +4.9% over one month, +83.1% over six months, +116.2% over one year.
Short interest was 13.2M shares at the Oct 15 settlement, up 4.6% from the prior report (13.7% of float, 9.9 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| AMLXAmylyx Pharmaceuticals | $29.40 | +0.68% | +83.1% | — | — | — | $3.69B | |
| IRONDisc Medicine | $83.28 | +2.61% | +21.3% | — | — | — | $3.70B | Compare |
| ACADAcadia Pharmaceuticals | $21.47 | +4.38% | 0.0% | +16.4% | 10.2% | 9.7 | $3.70B | Compare |
| OGNOrganon & | $13.83 | −0.14% | +3.1% | −1.7% | 10.4% | 17.1 | $3.63B | Compare |
| PBLSParabilis Medicines | $30.36 | +3.79% | — | — | −45239.9% | — | $3.75B | Compare |
| XENEXenon Pharmaceuticals | $39.19 | +2.51% | −33.1% | — | — | — | $3.80B | Compare |
| VKTXViking Therapeutics | $27.97 | +7.21% | −13.4% | — | — | — | $3.57B | Compare |
| TNGXTango Therapeutics | $23.18 | +0.04% | −1.9% | −100.0% | — | — | $3.91B | Compare |
| DYNDyne Therapeutics | $18.54 | +2.71% | −1.6% | — | — | — | $3.46B | Compare |
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
